MARKET

HEPA

HEPA

Hepion Pharmaceuticals Inc
NASDAQ
1.020
-0.025
-2.39%
Opening 09:57 07/19 EDT
OPEN
1.010
PREV CLOSE
1.045
HIGH
1.020
LOW
1.010
VOLUME
977
TURNOVER
0
52 WEEK HIGH
11.07
52 WEEK LOW
0.9000
MARKET CAP
5.58M
P/E (TTM)
-0.1074
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at HEPA last week (0708-0712)?
Weekly Report · 4d ago
Weekly Report: what happened at HEPA last week (0701-0705)?
Weekly Report · 07/08 10:18
Weekly Report: what happened at HEPA last week (0624-0628)?
Weekly Report · 07/01 10:19
Weekly Report: what happened at HEPA last week (0617-0621)?
Weekly Report · 06/24 10:23
Weekly Report: what happened at HEPA last week (0610-0614)?
Weekly Report · 06/17 10:18
Weekly Report: what happened at HEPA last week (0603-0607)?
Weekly Report · 06/10 10:19
Weekly Report: what happened at HEPA last week (0527-0531)?
Weekly Report · 06/03 10:21
Weekly Report: what happened at HEPA last week (0520-0524)?
Weekly Report · 05/27 10:24
More
About HEPA
Hepion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of drug therapy for treatment of chronic liver diseases. The Company is developing a treatment for non-alcoholic steatohepatitis (NASH), hepatocellular carcinoma (HCC), and other chronic liver diseases. Its cyclophilin inhibitor, rencofilstat, is being developed to offer benefits to address multiple complex pathologies related to the progression of liver disease. It is developing rencofilstat as its lead molecule. Rencofilstat is a compound that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulate protein folding, in addition to other activities. It has developed and maintains an artificial intelligence deep machine learning (AI/ML) platform designed to understand disease processes and identify patients that are rencofilstat responders. In addition, its AI/ML can be used to further NASH and HCC clinical development programs.

Webull offers Hepion Pharmaceuticals Inc stock information, including NASDAQ: HEPA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HEPA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HEPA stock methods without spending real money on the virtual paper trading platform.